Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Primo N. Lara, Giorgio V. Scagliotti, Mark J. McKeage et al.|Journal of Clinical Oncology|2011

Cited by 320